Into a Deeper Understanding of CYP2D6’s Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders

• Published in: International journal of molecular sciences Vol. 25; no. 12; p. 6350
• Main Authors: Bondrescu, Mariana, Dehelean, Liana, Farcas, Simona, Dragan, Patricia Alexandra, Podaru, Carla Andreea, Popa, Laura, Andreescu, Nicoleta
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.06.2024; MDPI
• Subjects: Adult; Antipsychotic Agents - adverse effects; Antipsychotic Agents - therapeutic use; Antipsychotics; Cytochrome P-450 CYP2D6 - genetics; Cytochrome P-450 CYP2D6 - metabolism; Delusional disorder; Delusions; Dyskinesia; Dystonia; Enzymes; Epidemiology; Female; Genotype; Humans; Male; Metabolism; Metabolites; Middle Aged; Patient compliance; Plasma; Population; Psychosis; Psychotropic drugs; Risperidone; Risperidone - adverse effects; Risperidone - therapeutic use; Schizophrenia; Schizophrenia - drug therapy; Substance abuse treatment; Young Adult; Romania; CYP2D6; schizophrenia spectrum disorders; risperidone treatment

Schizophrenia spectrum disorders (SSD) are a group of diseases characterized by one or more abnormal features in perception, thought processing and behavior. Patients suffering from SSD are at risk of developing life-threatening complications. Pharmacogenetic studies have shown promising results on...